Artivion, Inc. (AORT) NYSE

42.64

+0.56(+1.33%)

Updated at October 20 01:27PM

Currency In USD

Artivion, Inc.

Address

1655 Roberts Boulevard N.W.

Kennesaw, GA 30144

United States of America

Phone

770 419 3355

Sector

Healthcare

Industry

Medical - Devices

Employees

1600

First IPO Date

February 12, 1993

Key Executives

NameTitlePayYear Born
Mr. James Patrick MackinChairman, President & Chief Executive Officer1.9M1967
Ms. Amy D. Horton CPAVice President & Chief Accounting Officer621,2651970
Mr. John E. DavisSenior Vice President & Chief Commercial Officer691,4661965
Ms. Jean F. Holloway Esq.Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary720,4241957
Mr. Lance A. Berry CPAExecutive Vice President of Finance & Chief Financial Officer1.07M1972
Dr. Marshall S. Stanton M.D.Senior Vice President of Clinical Research & Chief Medical Officer1.28M1957
Mr. Florian TyrsVice President of Global Operations01982
Mr. Matthew A. GetzVice President of Human Resources & Chief Human Resources Officer01969
Dr. Robert C. Thomson Ph.D.Vice President of Research & Development01970

Description

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.